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AMP-activated protein kinase (AMPK) functions as a signaling hub to balance energy supply with
demand. Phosphorylation of activation loop Thr172 has been considered as an essential step in
AMPK activation. In this issue of Chemistry & Biology, Scott and colleagues show that the small molecule
direct AMPK activator, A-769662, bypasses this phosphorylation event and acts synergistically with AMP
on naive AMPK.Maintaining cellular energy balance is a
key process for cell function and sur-
vival. Over the recent years, the AMP-
activated protein kinase (AMPK) has
emerged as a major regulator of cellular
energy homeostasis. This serine/threo-
nine kinase, evolutionary conserved in
all eukaryotes, integrates multiple extra-
and intracellular input signals directly or
indirectly linked to limited energy avail-
ability to coordinate a wide array of
compensatory, protective, and energy-
sparing responses at the cellular, organ,
and organism levels. AMPK is ubiqui-
tously expressed and exists as a hetero-
trimeric complex comprising a catalytic a
subunit, a scaffolding b subunit, and a
regulatory g subunit.
The AMPK activation mechanism was
considered to involve two steps: an
obligatory covalent phosphorylation of
the a subunit Thr172 in the so-called
activation loop of the kinase domain
and a stimulatory allosteric binding of
AMP to cystathionine-beta-synthase
(CBS) motifs in the g subunit. Covalent
activation is complex, because it in-
volves stimulated phosphorylation by
several upstream kinases (LKB1 and
CaMKKb) and inhibited dephosphoryla-
tion by phosphatases, both favored by
b subunit myristoylation and binding of
AMP (and to a lesser extend ADP) to
the different allosteric activation sites
within the g subunit (Oakhill et al.,
2011; Xiao et al., 2011). There seems
to exist a delicate phosphorylation/
dephosphorylation equilibrium, where
the dephosphorylation step is of major
regulatory importance. However, notmuch is known about the nature of the
phosphatases, because it may depend
on both cell type and environmental con-
ditions. Allosteric activation of AMPK is
even more intricate, because it is
orchestrated by various structural ele-
ments in different AMPK subunits
(Figure 1). Crystal structures of AMPK
bound to either AMP or ATP revealed
that only three of the four potential
nucleotide-binding sites in the g subunit
contribute to nucleotide regulation
(Chen et al., 2012; Xiao et al., 2011,
2013). Because the activating ligand is
bound on the g subunit and the kinase
domain is in the a subunit, intersubunit
communication has to occur when
switching to fully active states (Figure 1).
Valuable insight has been provided by
core structures of AMPK heterotrimers
showing AMP-induced conformational
changes in the AMPK holocomplex and
even the g subunit (Figure 1) (Chen
et al., 2012). Important regulatory fea-
tures for this conformational switch are
provided by a subunit flexible compo-
nents, the autoinhibitory domain (AID),
and the a-RIM/a-hook interacting with
the exchangeable nucleotide-binding
sites on the g subunit, offering a
signaling mechanism for nucleotide allo-
steric regulation (Chen et al., 2012, 2013;
Xiao et al., 2011, 2013). Given these
complex regulatory mechanisms, it is
not surprising that, despite intense
research, the AMPK ‘‘activation switch’’
is still not entirely understood.
Because of its critical role in maintain-
ing cellular energy homeostasis, AMPK
has attracted broad interest as a primeChemistry & Biology 21, May 22, 2014target for pharmacological intervention
in several energy-related pathologies.
This has led to increased efforts to
develop direct AMPK-activating drugs.
In this issue of Chemistry and Biology,
Scott et al. (2014) refine the mechanism
of action of the first described small
molecule direct AMPK activator, the thie-
nopyridone drug A-769662, identified by
Abbott laboratories (Cool et al., 2006).
Previous studies have reported that
A-769662 activates AMPK both allosteri-
cally and by inhibiting the dephosphory-
lation of AMPK on Thr172 (Cool et al.,
2006; Sanders et al., 2007). However,
in contrast to adenine nucleotides,
A-769662 does not bind the g subunit
but requires the b1 regulatory subunit
and its autophosphorylation at Ser108
within the carbohydrate binding module
(CBM) (Figure 1) (Sanders et al., 2007;
Scott et al., 2008).
Previous studies reported one intrigu-
ing observation. A-769662 can trigger
robust phosphorylation of the AMPK
downstream target acetyl-CoA carbox-
ylase in hepatocytes in absence of a
subunit Thr172 phosphorylation (Foretz
et al., 2010; Goransson et al., 2007),
raising some doubt about the require-
ment of AMPK activation loop phosphor-
ylation for A-769662 action. Scott et al.
(2014) now use catalytically inactive,
bacterially expressed AMPK a1b1g1,
which is not phosphorylated on Thr172
and show a 65-fold activation with A-
769662. However, other studies demon-
strated that purified liver AMPK treated
with phosphatase was refractory to A-
769662 allosteric activation, suggestingª2014 Elsevier Ltd All rights reserved 567
Figure 1. AMPK Activation
Binding of the activating AMPK ligands AMP (g subunit) and A-769662
(b subunit) has to be transduced to the a subunit kinase domain for activation
involving conformational changes (see arrows).
Top: AMPK subunits a (green), b (blue), and g (magenta) (PDB 1CFF; Xiao
et al., 2013) with a subunit kinase domain, activation loop (AL), and regula-
tory interacting motif (RIM; Chen et al., 2013) indicated (dark green) and b
subunit carbohydrate binding module (CBM) labeled; sequences missing
in the structure (dashed) include the a-autoinhibitory domain (AID). The figure
shows (in spacefill representation) the activation-relevant phosphosites
(a-T172 in the activation loop and b-S108 in the CBM; red-brown) and
ligands co-crystallized in the structure: allosteric AMPK-activators
A-769662 (red) and AMP (orange/yellow) and the kinase inhibitor Stauro-
sporine in the active site (green).
Bottom: table summarizing the effect of phosphorylation or mutation of a
subunit T172 and b subunit S108 on AMPK activation by AMP, A-769662,
or both (Scott et al., 2014).
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another site is required for
drug activation. Scott et al.
(2014) now reveal that
bacterially expressed AMPK
a1b1g1 is strongly phos-
phorylated at b subunit
Ser108, a phosphosite already
linked to A-769662 activa-
tion (Sanders et al., 2007).
Indeed, AMPKT172A/S108E and
AMPKT172A/S108D mutants
lacking phosphorylation at
Thr172, but mimicking the
one at Ser108, and treated in
addition with l phosphatase,
retained full activation by
A-769662, demonstrating that
phosphorylation on b subunit
Ser108 alone is sufficient to
render AMPK sensitive to
A-769662 allosteric activation
(Figure 1, bottom). The authors
also identify Ser108phosphor-
ylation as a cis-autophos-
phorylation event, without
excluding the existence of a
specific upstream kinase, but
nevertheless raising questions
aboutA-769662effects in vivo.
Indeed, if b subunit Ser108 is
only autophosphorylated, it is
entirely dependent on AMPK
activity. This would explain
why A-769662 activation is
completely blunted in cells
lacking LKB1 (Foretz et al.,
2010; Goransson et al., 2007).
Foretz et al. (2010) had pre-
viously found that a combined
treatment with the two AMPK
activators A-769662 and the
AMP analog 5-aminoimida-
zole-4-carboxamide 1-b-D-
ribofuranoside (AICAR), which
act on different binding sites
(b-CMB and g-CBS, respec-
tively), exhibits a synergistic
effect on AMPK phosphoryla-
tion and its downstream
targets. Scott et al. (2014)
next looked to extend their
findings and tested whether
combining A-769662 and
AMP have synergistic effects
on activation of AMPKcomplexes containing AMPKT172A/S108E,
AMPKT172A/S108D, and AMPKT172A/S108A
mutants. Here they employed recombi-568 Chemistry & Biology 21, May 22, 2014 ªnant AMPK complexes expressed in
mammalian cells containing all posttrans-
lational modifications (e.g., myristoylation2014 Elsevier Ltd All rights reservedof b subunit) required to
fully activate AMPK. Inter-
estingly, A-769662-activation
of AMPKT172A/S108E and
AMPKT172A/S108D was further
increased 2-fold to 4-fold
when combined with AMP.
A surprising finding was
the dramatic activation of
AMPKT172A/S108A mutant fol-
lowing incubation with both
A-769662 and AMP. This
result is unexpected and
novel. The authors demon-
strate for the first time that
AMPK can be activated in the
absence of phosphorylation
at both b subunit Ser108 and
a subunit Thr172. This syner-
gistic AMPK activation was
not mediated by autophos-
phorylation and occurred
exclusively via an allosteric
mechanism. Another impor-
tant finding is that the com-
bined action of A769662 and
AMP is entirely dependent on
b-CBM, because AMPKT172A
mutants lacking this regulatory
domain are insensitive to syn-
ergistic allosteric activation.
One plausible explanation is
that A-769662 binding is crit-
ical to induce a conformational
change in the AMPK holocom-
plex, leading to the rearrange-
ment and stabilization of the
unphosphorylated activation
loop to enhance AMPK activa-
tion upon AMP binding (Fig-
ure 1). This is consistent with
the recent structural studies
showing that A-769662 bind-
ing facilitates movement in
the aC-helix in the kinase
domain to interact with the
C-interacting helix in the
CBM, thus making an impor-
tant contribution in the allo-
steric activation of AMPK
(Xiao et al., 2013). Strikingly,
ADP, which does not cause
AMPK Thr172 phosphoryla-
tion (Oakhill et al., 2011; Xiao
et al., 2011), was unable
to activate AMPKT172A/S108A
mutant when combined with A-769662.
To dig deeper in the mechanism of
AMPK conformational changes, Scott
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vidual CBS domains within the g subunit.
When g subunit residues Asp90 (site 1),
Asp245 (site 3), and Asp317 (site 4) were
individually exchanged with Ala, syner-
gistic activation induced by the combined
action of A-769662 and AMP was
severely blunted.
Collectively, Scott et al. (2014) report
how AMPK can be activated via a purely
allosteric mechanism, bypassing the
requirement of a subunit Thr172 and b
subunit Ser108 phosphorylation. These
findings are highly relevant for the devel-
opment of specific directly-acting AMPK
agonists and the future direction of
AMPK-based therapy in disease-focused
research. This study is also critical to our
understanding of how to target AMPK
pharmacologically, depending on the
cellular context (e.g., genetic loss of up-
stream kinase and expression of b1- and
b2-subunits). There have been two recent
reports evaluating the functional effects of
A-769662 in combination with AICAR or
indirect AMPK activators (metformin,
phenformin, oligomycin, and hypoxia)
acting via the elevation of cellular AMP
levels. Consistent with enhanced AMPK
activation by co-treatment, inhibition of
hepatic lipogenesis (Ducommun et al.,
2014) and activation of cardiac glucosetransport (Timmermans et al., 2014)
were greatly improved compared with
A-769662 alone. These results reinforce
the view that combinatorial treatments
would be of value to enhance AMPK acti-
vation. In addition, such treatments could
help to reduce the amount of drugs
administrated to patients and better
balance tolerability and efficacy. Future
research will have to elucidate the benefi-
cial effects of metformin in combination
with various AMPK activators targeting
the A-769662 binding site for patients
suffering with type 2 diabetes, insulin
resistance, cardiovascular diseases, and
also cancer.REFERENCES
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In this issue of Chemistry & Biology, Hari and colleagues show that conformation-selective ATP-competitive
kinase inhibitors have distinct noncatalytic effects on Erk2, including the ability to modulate protein-protein
interactions outside the ATP-binding site. These findings enhance our knowledge about the diverse array of
activities in which kinase inhibitors can target signaling pathways.Elucidating imatinib’s binding mode with
c-Abl prompted the development of
myriad kinase inhibitors that stabilize (or
bind to) the inactive DFG-out conforma-
tion (Figure 1A). It was originally believed
that the DFG-out conformation was non-
conserved across the kinome and there-fore explained the selectivity of imatinib.
However, recent studies have shown
that the inactive DFG-out conformation
is not unique and inhibitors that stabi-
lize this conformation are not inherently
more selective than inhibitors that bind
the active conformation.Although there aremanyDFG-out inhib-
itors (also known as type II kinase inhibi-
tors) known, only recently has there been
an appreciation that conformation-selec-
tive inhibitors, including DFG-out inhibi-
tors, can uniquely modulate noncatalytic
functions of kinases. The first reportª2014 Elsevier Ltd All rights reserved 569
